Articles related to TYPE 2 DIABETES

The combination of structured lifestyle interventions with targeted pharmacotherapy demonstrates significant potential for achieving substantial weight loss in patients with type 2 diabetes.

Ozempic (semaglutide) offers effective glycemic control and weight loss benefits for type 2 diabetes patients, but comes with a range of potential side effects. Physicians should be prepared to discuss common gastrointestinal issues, rare but serious complications, and special considerations for pregnant or postmenopausal patients.

Recent research comparing SGLT2 inhibitors and dulaglutide in older patients with type 2 diabetes suggests a potential difference in dementia risk. The study estimated a risk ratio of 0.81 (CI, 0.56 to 1.16) for SGLT2 inhibitors compared to dulaglutide.

New guidelines endorse the use of continuous glucose monitors and insulin pumps in hospital settings, potentially improving glycemic control while reducing hypoglycemia risk in noncritically ill patients.

SGLT-2 inhibitors offer benefits beyond glucose control, potentially addressing the systemic inflammatory components of metabolic diseases like diabetes, heart failure, and gout.

Patients taking semaglutide for diabetes were more than four times more likely to develop NAION compared to those on other diabetes medications, while those using it for obesity had a seven-fold increased risk.